Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Nami Mori"'
Autor:
Atsuhiro Morita, Nobuharu Tamaki, Haruhiko Kobashi, Nami Mori, Keiji Tsuji, Shintaro Takaki, Chitomi Hasebe, Takehiro Akahane, Hironori Ochi, Toshie Mashiba, Naohito Urawa, Hideki Fujii, Akeri Mitsuda, Masahiko Kondo, Chikara Ogawa, Yasushi Uchida, Ryoichi Narita, Hiroyuki Marusawa, Yoshihito Kubotsu, Tomomichi Matsushita, Masaya Shigeno, Hideo Yoshida, Katsuaki Tanaka, Eisuke Okamoto, Toyotaka Kasai, Toru Ishii, Kazuhiko Okada, Masayuki Kurosaki, Namiki Izumi
Publikováno v:
JGH Open, Vol 8, Iss 4, Pp n/a-n/a (2024)
Abstract Background and aim In patients with chronic hepatitis C, 8 weeks of glecaprevir and pibrentasvir (GLE/PIB) treatment for chronic hepatitis (non‐cirrhosis) and 12 weeks for cirrhosis have been approved in Japan. However, whether 8 weeks of
Externí odkaz:
https://doaj.org/article/0d9873a1fd55472ea90b8aee2ad5fcad
Autor:
Shun Ishido, Nobuharu Tamaki, Masayuki Kurosaki, Nami Mori, Keiji Tsuji, Chitomi Hasebe, Toshie Mashiba, Hironori Ochi, Yutaka Yasui, Takehiro Akahane, Koichiro Furuta, Haruhiko Kobashi, Hideki Fujii, Toru Ishii, Hiroyuki Marusawa, Masahiko Kondo, Atsunori Kusakabe, Hideo Yoshida, Yasushi Uchida, Toshifumi Tada, Shinichiro Nakamura, Akari Mitsuda, Chikara Ogawa, Hirotaka Arai, Toshimitsu Murohisa, Minoru Uebayashi, Namiki Izumi
Publikováno v:
JGH Open, Vol 7, Iss 6, Pp 424-430 (2023)
Abstract Background and Aim Hepatocellular carcinoma (HCC) surveillance in low‐risk patients (annual incidence
Externí odkaz:
https://doaj.org/article/b64a2bedcc15417daad694e97d928a4c
Autor:
Shigeki Yano, Tomokazu Kawaoka, Shintaro Yamasaki, Yusuke Johira, Masanari Kosaka, Yuki Shirane, Ryoichi Miura, Kei Amioka, Kensuke Naruto, Kenji Yamaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Daiki Miki, Masataka Tsuge, Yuji Teraoka, Hirotaka Kouno, Shintaro Takaki, Nami Mori, Keiji Tsuji, Shiro Oka
Publikováno v:
Cancers, Vol 15, Iss 22, p 5406 (2023)
A total of 137 HCC patients treated with atezolizumab plus bevacizumab from October 2020 to September 2022 were enrolled. The median overall survival (OS) and progression-free survival (PFS) from the beginning of atezolizumab plus bevacizumab were 21
Externí odkaz:
https://doaj.org/article/aeace0015ad44ea68812d0ef7a8b225f
Autor:
Toshifumi Tada, Masayuki Kurosaki, Nobuharu Tamaki, Yutaka Yasui, Nami Mori, Keiji Tsuji, Chitomi Hasebe, Koji Joko, Takehiro Akahane, Koichiro Furuta, Haruhiko Kobashi, Hideki Fujii, Toru Ishii, Hiroyuki Marusawa, Masahiko Kondo, Yuji Kojima, Hideo Yoshida, Yasushi Uchida, Shinichiro Nakamura, Namiki Izumi
Publikováno v:
JGH Open, Vol 6, Iss 7, Pp 487-495 (2022)
Abstract Background and Aim To validate a composite predictive model for hepatocellular carcinoma (HCC) development in patients with advanced liver fibrosis associated with chronic hepatitis C virus (HCV) who have received direct‐acting antiviral (
Externí odkaz:
https://doaj.org/article/1245a6fe39404562bd16b6582e04534d
Autor:
Nobuharu Tamaki, Masayuki Kurosaki, Yutaka Yasui, Nami Mori, Keiji Tsuji, Chitomi Hasebe, Kouji Joko, Takehiro Akahane, Koichiro Furuta, Haruhiko Kobashi, Hiroyuki Kimura, Hitoshi Yagisawa, Hiroyuki Marusawa, Masahiko Kondo, Yuji Kojima, Hideo Yoshida, Yasushi Uchida, Toshifumi Tada, Shinichiro Nakamura, Satoshi Yasuda, Hidenori Toyoda, Rohit Loomba, Namiki Izumi
Publikováno v:
Hepatology Communications, Vol 6, Iss 3, Pp 461-472 (2022)
The identification of patients with advanced fibrosis who do not need any further hepatocellular carcinoma (HCC) surveillance after the eradication of hepatitis C is pivotal. In this study, we developed a simple serum‐based risk model that could id
Externí odkaz:
https://doaj.org/article/b270c985294642f8ba44b40f73ac4f16
Autor:
Toshifumi Tada, Masayuki Kurosaki, Nobuharu Tamaki, Yutaka Yasui, Nami Mori, Keiji Tsuji, Chitomi Hasebe, Koji Joko, Takehiro Akahane, Koichiro Furuta, Haruhiko Kobashi, Hiroyuki Kimura, Hitoshi Yagisawa, Hiroyuki Marusawa, Masahiko Kondo, Yuji Kojima, Hideo Yoshida, Yasushi Uchida, Shinichiro Nakamura, Namiki Izumi
Publikováno v:
JGH Open, Vol 6, Iss 1, Pp 20-28 (2022)
Abstract Background and Aim The pathogenic process underlying the development of hepatocellular carcinoma (HCC) is not yet clear in patients with hepatitis C virus (HCV) who have received direct‐acting antiviral (DAA) therapy and achieved sustained
Externí odkaz:
https://doaj.org/article/32a143b3a92949e48869ab1e29bd215b
Autor:
Kei Amioka, Tomokazu Kawaoka, Takahiro Kinami, Shintaro Yamasaki, Masanari Kosaka, Yusuke Johira, Shigeki Yano, Kensuke Naruto, Yuwa Ando, Yasutoshi Fujii, Shinsuke Uchikawa, Atsushi Ono, Masami Yamauchi, Michio Imamura, Yumi Kosaka, Kazuki Ohya, Nami Mori, Shintaro Takaki, Keiji Tsuji, Keiichi Masaki, Yoji Honda, Hirotaka Kouno, Hioshi Kohno, Kei Morio, Takashi Moriya, Noriaki Naeshiro, Michihiro Nonaka, Yasuyuki Aisaka, Takahiro Azakami, Akira Hiramatsu, Hiroshi Aikata, Shiro Oka
Publikováno v:
Cancers, Vol 14, Iss 20, p 5066 (2022)
Transarterial chemoembolization (TACE) has been the standard treatment for intermediate-stage, unresectable hepatocellular carcinoma (u-HCC). However, with recent advances in systemic therapy and the emergence of the concept of TACE-refractory or -un
Externí odkaz:
https://doaj.org/article/299fc594206f4964ae6d1d68dc73f92f
Autor:
Kei Amioka, Tomokazu Kawaoka, Masanari Kosaka, Yusuke Johira, Yuki Shirane, Ryoichi Miura, Serami Murakami, Shigeki Yano, Kensuke Naruto, Yuwa Ando, Yumi Kosaka, Yasutoshi Fujii, Kenichiro Kodama, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Michio Imamura, Nami Mori, Shintaro Takaki, Keiji Tsuji, Keiichi Masaki, Yoji Honda, Hirotaka Kouno, Hiroshi Kohno, Takashi Moriya, Noriaki Naeshiro, Michihiro Nonaka, Hideyuki Hyogo, Yasuyuki Aisaka, Takahiro Azakami, Akira Hiramatsu, Hiroshi Aikata
Publikováno v:
Cancers, Vol 14, Iss 2, p 320 (2022)
The association between radiological response and overall survival (OS) was retrospectively evaluated in patients treated with lenvatinib as a first-line systemic treatment for unresectable hepatocellular carcinoma. A total of 182 patients with Child
Externí odkaz:
https://doaj.org/article/9a5f88edd5114d71a0095fb22d484bf6
Autor:
Kosuke Saito, Tatehiro Kagawa, Keiji Tsuji, Yuji Kumagai, Ken Sato, Shotaro Sakisaka, Naoya Sakamoto, Mitsuhiko Aiso, Shunji Hirose, Nami Mori, Rieko Tanaka, Toshio Uraoka, Kazuhide Takata, Koji Ogawa, Kazuhiko Mori, Motonobu Sato, Takayoshi Nishiya, Kazuhiko Takamatsu, Noriaki Arakawa, Takashi Izumi, Yasuo Ohno, Yoshiro Saito, Hajime Takikawa
Publikováno v:
Metabolites, Vol 10, Iss 9, p 355 (2020)
Drug-induced liver injury (DILI) is a major adverse event caused by drug treatment, which can be categorized into three types: hepatocellular, mixed, and cholestatic. Although nearly every class of drugs can cause DILI, an overall understanding of li
Externí odkaz:
https://doaj.org/article/fb4ff2dbe5c84f8e8d0740efbb71510a
Autor:
Shintaro Takaki, Masayuki Kurosaki, Nami Mori, Keiji Tsuji, Hironori Ochi, Hiroyuki Marusawa, Shinichiro Nakamura, Toshifumi Tada, Ryoichi Narita, Yasushi Uchida, Takehiro Akahane, Masahiko Kondo, Atsunori Kusakabe, Koichiro Furuta, Haruhiko Kobashi, Hirotaka Arai, Michiko Nonogi, Takashi Tamada, Chitomi Hasebe, Chikara Ogawa, Takashi Sato, Nobuharu Tamaki, Yutaka Yasui, Kaoru Tsuchiya, Namiki Izumi
Publikováno v:
Investigational New Drugs. 41:340-349